Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316554 | 0.94 | ADRB2 (0.48) | ADRB2CYP1A2CYP2A6TAAR1IGF1R | |
| SCHEMBL21084402 | 0.91 | ADRB2 (0.48) | ADRB2IGF1RALOX15PDPK1 | |
| SCHEMBL13608766 | 0.87 | CYP1A2 (0.48) | ADRB2CYP1A2CYP2A6TAAR1IGF1R | |
| SCHEMBL16674489 | 0.85 | ADRB2 (0.49) | ADRB2IGF1RALOX15PDPK1 | |
| SCHEMBL25232794 | 0.82 | HTR3E (0.48) | ADRB2TAAR1IGF1RALOX15C3AR1 | |
| SCHEMBL14356992 | 0.82 | TAAR1 (0.43) | ADRB2TAAR1C3AR1IDO1PDPK1 | |
| SCHEMBL14080940 | 0.82 | ADRB2 (0.43) | ADRB2IDO1PDPK1 | |
| SCHEMBL14937214 | 0.82 | ESR1 (0.50) | ADRB2TAAR1IGF1RALOX15 | |
| SCHEMBL16212606 | 0.82 | MAOB (0.50) | ADRB2PDPK1 | |
| SCHEMBL16212624 | 0.82 | TAAR1 (0.43) | ADRB2TAAR1IDO1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741944-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-8546441-B2 | PDK-1/AKT signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541460-B2 | Phosphoinositide-dependent kinase-1 (PDK-1) inhibitors; for the treatment and prevention of cancer in humans; 4-[5-(2-Phenanthracenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenecarboxamide | THE OHIO STATE UNIVERSITY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8445483-B1 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | disclosed |
| US-8080574-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-8039502-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090281328-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7576116-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090111799-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | US | disclosed |
| US-20080269309-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080146815-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | ADRB2 428/4885CYP1A2 2897/4885CYP2A6 4317/4885 |
| US-20090281328-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, PDXK, PI4KA | ADRB2 805/4885CYP1A2 2119/4885CYP2A6 3508/4885 |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | ADRB2 2874/4885CYP1A2 4788/4885CYP2A6 4860/4885 |
| US-20080146815-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, PDXK, PI4KA | ADRB2 817/4885CYP1A2 2123/4885CYP2A6 3515/4885 |
| US-20080269309-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | ADRB2 428/4885CYP1A2 2897/4885CYP2A6 4317/4885 |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | ADRB2 2874/4885CYP1A2 4788/4885CYP2A6 4860/4885 |
| US-20090111799-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | ADRB2 2874/4885CYP1A2 4788/4885CYP2A6 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.